Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Yutiq Drug
Yutiq · 1 trial · 4 indications
The primary endpoint of recurrence rate of uveitis will be assessed at the 6-month visit. The clinical definition of intraocular inflammation recurrence is (1) a 2-step or more increase in number of cells in the anterior chamber per high-powered field (x1.6 using a 1-mm beam), (2) a 2-step or more increase in vitreous haze, or (3) a deterioration in BCVA of 15 letters or more. In each case, the etiology of the change must be only due to noninfectious uveitis.
| Arm | Type | Description |
|---|---|---|
| Treatment Arm | EXPERIMENTAL | This group will receive two YUTIQ implants at day 1. |
| Control Arm | SHAM_COMPARATOR | This group will receive two sham injections at day 1. |
| Name | Type | Description |
|---|---|---|
| Yutiq 0.18 MG Drug Implant | DRUG | YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection |
| Sham Injection | OTHER | Sham injection |
Inclusion Criteria: General Inclusion Criteria: 1. Male or non-pregnant female in good general health at least 18 years of age, understands the language of the informed consent, and is willing and able to provide written informed consent and sign/date a health information release (HIPAA form) befo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Roivant Sciences Ltd. | ROIV | 1 | PHASE3 | Brepocitinib |
| Eli Lilly and Company | LLY | 1 | PHASE3 | Baricitinib, Adalimumab |
| ANI Pharmaceuticals, Inc. | ANIP | 1 | PHASE3 | Yutiq Drug |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |